Hyperkalemia Clinical Trial
Official title:
The Effect of Mannitol on Intraoperative Serum Potassium in Patients Undergoing Craniotomy:an Observational Study
Verified date | January 2017 |
Source | The Affiliated Hospital of Xuzhou Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an observational study designed to research the effect of mannitol on the concentration of intraoperative serum potassium in patients undergoing craniotomy, and to guide the safe use of mannitol during craniotomy.
Status | Completed |
Enrollment | 30 |
Est. completion date | June 1, 2017 |
Est. primary completion date | June 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - age 18 to 70 - American Society of Anesthesiologists physical status I to II - liver and kidney function is normal - preoperative concentration of serum potassium was from 3.5 to 5.5 mmol/L Exclusion Criteria: - history or presence of congestive heart failure (New York Heart Association class III to IV) - history or presence of renal failure(diabetes insipidus, or syndrome of inappropriate antidiuretic hormone secretion) - intraoperative blood transfusion |
Country | Name | City | State |
---|---|---|---|
China | The Affiliated Hospital of Xuzhou Medical University | Xuzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The Affiliated Hospital of Xuzhou Medical University |
China,
Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int. 1997 Oct;52(4):886-94. Review. — View Citation
Fanous AA, Tick RC, Gu EY, Fenstermaker RA. Life-Threatening Mannitol-Induced Hyperkalemia in Neurosurgical Patients. World Neurosurg. 2016 Jul;91:672.e5-9. doi: 10.1016/j.wneu.2016.04.021. Epub 2016 Apr 13. — View Citation
Hirota K, Hara T, Hosoi S, Sasaki Y, Hara Y, Adachi T. Two cases of hyperkalemia after administration of hypertonic mannitol during craniotomy. J Anesth. 2005;19(1):75-7. — View Citation
Maas AI, Dearden M, Teasdale GM, Braakman R, Cohadon F, Iannotti F, Karimi A, Lapierre F, Murray G, Ohman J, Persson L, Servadei F, Stocchetti N, Unterberg A. EBIC-guidelines for management of severe head injury in adults. European Brain Injury Consortium. Acta Neurochir (Wien). 1997;139(4):286-94. — View Citation
Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth. 1987 Sep;34(5):442-6. Review. — View Citation
Palma L, Bruni G, Fiaschi AI, Mariottini A. Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon. A study on 21 patients. J Neurosurg Sci. 2006 Sep;50(3):63-6. — View Citation
Quentin C, Charbonneau S, Moumdjian R, Lallo A, Bouthilier A, Fournier-Gosselin MP, Bojanowski M, Ruel M, Sylvestre MP, Girard F. A comparison of two doses of mannitol on brain relaxation during supratentorial brain tumor craniotomy: a randomized trial. Anesth Analg. 2013 Apr;116(4):862-8. doi: 10.1213/ANE.0b013e318282dc70. Epub 2013 Jan 25. — View Citation
Rozet I, Tontisirin N, Muangman S, Vavilala MS, Souter MJ, Lee LA, Kincaid MS, Britz GW, Lam AM. Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance. Anesthesiology. 2007 Nov;107(5):697-704. — View Citation
Seto A, Murakami M, Fukuyama H, Niijima K, Aoyama K, Takenaka I, Kadoya T. Ventricular tachycardia caused by hyperkalemia after administration of hypertonic mannitol. Anesthesiology. 2000 Nov;93(5):1359-61. — View Citation
Stewart PA. Modern quantitative acid-base chemistry. Can J Physiol Pharmacol. 1983 Dec;61(12):1444-61. — View Citation
The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Initial management. J Neurotrauma. 2000 Jun-Jul;17(6-7):463-9. — View Citation
WINTERS RW, SCAGLIONE PR, NAHAS GG, VEROSKY M. THE MECHANISM OF ACIDOSIS PRODUCED BY HYPEROSMOTIC INFUSIONS. J Clin Invest. 1964 Apr;43:647-58. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the concentration of serum potassium | measured by arterial blood gas analysis | two hours within infusioning mannitol |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03172702 -
Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
|
Phase 3 | |
Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
Recruiting |
NCT05766839 -
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
|
Phase 2 | |
Completed |
NCT02609841 -
POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
|
N/A | |
Recruiting |
NCT06277128 -
A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.
|
Phase 2 | |
Recruiting |
NCT04789239 -
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
|
Phase 2 | |
Completed |
NCT05029310 -
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
|
Phase 4 | |
Terminated |
NCT04443608 -
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
|
Phase 4 | |
Completed |
NCT02607085 -
REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study
|
N/A | |
Completed |
NCT03283267 -
A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
|
Phase 1 | |
Recruiting |
NCT06036823 -
5 Versus 10 Units of Insulin in Hyperkalemia Management
|
Phase 4 | |
Recruiting |
NCT05173584 -
Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.
|
Phase 4 | |
Completed |
NCT05184998 -
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
|
||
Completed |
NCT01737697 -
Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
|
Phase 3 | |
Completed |
NCT01493024 -
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
|
Phase 2 | |
Completed |
NCT04207203 -
Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
|
N/A | |
Completed |
NCT05382988 -
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
|
Phase 3 | |
Completed |
NCT04217590 -
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
|
Phase 3 | |
Recruiting |
NCT03096561 -
Measurement of Serum Potassium Rate During Accidental Hypothermia.
|
N/A | |
Completed |
NCT03326583 -
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
|
Phase 2 |